[go: up one dir, main page]

DE60135482D1 - Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen - Google Patents

Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen

Info

Publication number
DE60135482D1
DE60135482D1 DE60135482T DE60135482T DE60135482D1 DE 60135482 D1 DE60135482 D1 DE 60135482D1 DE 60135482 T DE60135482 T DE 60135482T DE 60135482 T DE60135482 T DE 60135482T DE 60135482 D1 DE60135482 D1 DE 60135482D1
Authority
DE
Germany
Prior art keywords
treatment
proliferative diseases
eukaryontic
cell devices
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135482T
Other languages
English (en)
Inventor
Christophe Echeverri
Pierre Goenczy
Anthony Hyman
Steven Jones
Karen Oegema
Matthew Kirkham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Original Assignee
Cenix BioScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix BioScience GmbH filed Critical Cenix BioScience GmbH
Application granted granted Critical
Publication of DE60135482D1 publication Critical patent/DE60135482D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60135482T 2000-11-09 2001-11-09 Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen Expired - Lifetime DE60135482D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24675000P 2000-11-09 2000-11-09
PCT/EP2001/013034 WO2002038805A2 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
DE60135482D1 true DE60135482D1 (de) 2008-10-02

Family

ID=22932039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135482T Expired - Lifetime DE60135482D1 (de) 2000-11-09 2001-11-09 Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen

Country Status (9)

Country Link
US (1) US7368248B2 (de)
EP (1) EP1334123B1 (de)
JP (1) JP2004526421A (de)
AT (1) ATE405585T1 (de)
AU (2) AU2483802A (de)
CA (1) CA2428438C (de)
DE (1) DE60135482D1 (de)
DK (1) DK1334123T3 (de)
WO (1) WO2002038805A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20070003520A1 (en) * 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2007039454A1 (en) 2005-09-20 2007-04-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siran
PT2129680E (pt) 2007-03-21 2015-08-28 Brookhaven Science Ass Llc Composições combinadas de gancho de cabelo e antissentido e métodos para modulação da expressão
CN102686729B (zh) 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
US7368248B2 (en) 2008-05-06
WO2002038805A3 (en) 2003-02-13
WO2002038805A2 (en) 2002-05-16
CA2428438C (en) 2012-09-25
AU2483802A (en) 2002-05-21
EP1334123B1 (de) 2008-08-20
JP2004526421A (ja) 2004-09-02
AU2002224838B2 (en) 2006-07-27
DK1334123T3 (da) 2009-01-12
EP1334123A2 (de) 2003-08-13
WO2002038805A8 (en) 2007-07-05
CA2428438A1 (en) 2002-05-16
US20040048277A1 (en) 2004-03-11
AU2002224838B9 (en) 2007-02-08
ATE405585T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
DE602005011279D1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE397754T1 (de) Verwendung von sc6 für die diagnose und behandlung von bustkarzinom
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
DE60328690D1 (de) 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69926400D1 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
ATE456053T1 (de) Na+, k+-atpase-expression bei zervixdysplasie und krebs
ATE428437T1 (de) Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
WO2005025624A3 (en) The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition